AcquisitionOct 21, 2026Pending
Hot🇳🇱 Netherlands
QNQIAGEN N.V.EPEQT Private Equity
Healthcare › Biotechnology
Enterprise value$12.1BEnterprise value · As stated in filing
AnnouncedOct 21, 2026
ConsiderationCash
StructureTender offer
RegionEurope
Cross-borderYes
Contingent paymentNo
Overview
EQT Private Equity agreed to acquire QIAGEN N.V. through an all-cash voluntary public takeover offer at €46.50 per share, valuing QIAGEN at approximately €10.8 billion in enterprise value.
Deal rationale
QIAGEN believes the transaction will provide the best environment for its next growth phase, giving it greater flexibility to invest for the long term under private ownership while providing shareholders with attractive and certain cash value.
AI-generated from the SEC filingPendingHealthcare › BiotechnologyNetherlandsEurope
Timeline
Valuation and terms
| Equity value | Undisclosed | |
|---|---|---|
| Enterprise value | $12.1B | Headline figure |
| Original currency | Enterprise €10.8B | As stated in filing |
| Consideration | Cash |
Advisors
Buy-side
DBDeutsche BankJJefferiesMSMorgan Stanley
Sell-side
GSGoldman SachsMMoelis & CompanyPWPerella Weinberg Partners
Parties
Target
QNQIAGEN N.V.
- Headquarters
- Netherlands
- Ticker
- QGEN
Acquirer
EPEQT Private Equity
- Headquarters
- Sweden
- Ticker
- —